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Oncoplastic Breast Surgery has become standard of care in the management of Breast Cancer patients.
These guidelines written by an Expert Advisory Group; convened by the Association of Breast Surgery
(ABS) and the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS), are
designed to provide all members of the breast cancer multidisciplinary team (MDT) with guidance on the
best breast surgical oncoplastic and reconstructive practice at each stage of a patient's journey, based on
current evidence. It is hoped they will also be of benefit to the wide range of professionals and service
commissioners who are involved in this area of clinical practice.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Statement of purpose
These guidelines were developed to optimise key clinical and
patient-reported outcomes experienced by patients undergoing
partial and total breast reconstruction. They are designed to com-
plement existing guidelines available on the Association of Breast
Surgery (ABS) Guidance Platform [1] and the British Association of
Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS) clinical
guidance and regulations site [2].
These oncoplastic guidelines also apply to women requesting
risk reducing surgery and the very small number of men who
request or require reconstructive surgery.
The purpose of these Guidelines is to provide all members of the
breast cancer multidisciplinary team (MDT) with guidance on theartin).
Ltd. This is an open access article ubest breast surgical oncoplastic and reconstructive practice at each
stage of a patient's journey, based on current evidence. It is hoped
they will also be of benefit to the wide range of professionals and
service commissioners who are involved in this area of clinical
practice.
Methods
A multidisciplinary working group was convened by the ABS
and the BAPRASwith expertise in the diagnosis, support, treatment
and follow up of patients considering Oncoplastic Breast Surgery
(OPBS) to develop evidence-based recommendations. Previous
guidance [3] was reviewed and updated through consensus
meetings and by collaboration on a working document between
meetings. A draft document was sent to the executive of the ABS
and the BAPRAS for consultation and approved following final-
isation. The guidelines represent a consensus opinion on the
optimal management of patients having OPBS informed by peer-
review publications.
The Guidelines are not intended to be prescriptive or legallynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Ultimately, members of the MDT remain responsible for the treat-
ment of patients under their care.
Consideration of OPBS
OPBS should be considered in all patients who require surgery
following a breast cancer diagnosis. OPBS includes therapeutic
mammoplasty, partial breast reconstruction and total breast
reconstruction (immediate or delayed). If certain procedures are
not available locally then pathways should be established to ensure
timely referral to an appropriate centre.
Communication with patients about Breast Reconstruction (BR)
is detailed in the National Institute for Health and Care Excellence
(NICE) guideline NG101: Early and locally advanced breast cancer
diagnosis and treatment [4] and other national guidelines. For
delayed breast reconstruction (DBR) there should be a clear and
agreed referral pathway from primary and secondary care. No time
limit should be placed on performing DBR after mastectomy.
The following should be clearly documented for all patients as
part of the MDT discussion and clinic consultation:
 If a mastectomy is recommended the indication(s) should be
documented.
 Consideration of oncological options (neo-adjuvant therapy)
and/or oncoplastic techniqueswhichmay reduce the probability
of or avoid mastectomy or a significant defect following tradi-
tional breast conservation surgery.
 BR (immediate or delayed) should be considered in all suitable
patients in whom a mastectomy is recommended.
 If Oncoplastic Techniques or Breast Reconstruction are not
thought to be appropriate then the rationale for this should be
fully discussed and documented.
 The likely requirement for adjuvant radiotherapy.
 The likely requirement for genetic testing.
All womenmust have the opportunity to meet their breast team
and discuss options with their surgeon and Breast Care Nurse (BCN)
prior to admission.
Assessment for OPBS
The following factors should be considered when assessing
patients for OPBS and may influence the timing and choice of
techniques available for individual patients allowing for the pa-
tients' own preferences, expectations, goals and attitudes to risk.
Patient factors
The following patient factors should be considered:
 Local and systemic disease burden.
 Previous radiotherapy to the breast/chest wall.
 Familial and genetic risk factors.
 Co-morbidities
o Including BMI, Diabetes, connective tissue disorders and
cardiorespiratory conditions.
 Pre-existing shoulder or musculo-skeletal problems.
 Drug historyoe.g. immunosuppresants and anticoagulants.
Smoking history
oIncluding nicotine containing products.
 Occupation, activities and lifestyle.
 Likely impact of recovery time on family, employment and daily
activities.2273Oncological factors
 Oncological principles should not be compromised, and always
take precedence.
 Neo-adjuvant systemic therapy should be considered in
appropriate patients. This may benefit patients by reducing re-
quirements for mastectomy, OPBS complexity and volume of
excision in patients suitable for breast conservation.
 For Immediate Breast Reconstruction (IBR), the likelihood of
adjuvant treatment (in particular radiotherapy) may influence
decision making.
 Overall IBR does not lead to clinically significant delays to
adjuvant therapy however post-operative complications may be
associated with treatment delay [5].
 Where there are concerns that IBRmay lead to delays in primary
treatment; systemic neoadjuvant therapy, if appropriate, or DBR
may be considered. Significant delays to primary breast cancer
surgery may be associated with an increased risk of mortality
[6].
 Extent of planned skin resection and suitability for nipple
preservation should be discussed and clearly documented in
patients undergoing IBR.
 All relevant cancer treatment targets should apply and transfer
with the patient if referred to another centre.
 For patients referred for OPBS from a separate unit, a full
discharge summary should be sent back to the referring or
treating MDT, including copies of operative notes, histopathol-
ogy slides and/or reports and a post-discharge plan. A clear
process for continuing care and follow-up should be agreed
upon.Radiotherapy factors
Previous or adjuvant radiotherapy will influence decision mak-
ing with regards to OPBS and specific factors should be considered.
Oncoplastic Techniques
o Oncoplastic Breast Conservation Surgery with adjuvant
radiotherapy is associated with high rates of disease-free
survival, overall survival and low rates of local recurrence [7].
oPatients not suitable for adjuvant radiotherapy are usually
not good candidates for oncoplastic breast conservation
surgery. Implant Based Breast Reconstruction
oRadiotherapy is associated with higher rates of complica-
tions, implant loss rates and poorer cosmetic outcomes in
patients undergoing implant based breast reconstruction [8].
oThe use of implant only reconstruction in patients with
previous, or planned chest wall radiotherapy should be
considered carefully.
oUse of expanders incorporating integrated metal ports may
need to be discussed with local clinical oncology de-
partments to ensure device compatibility with adjuvant
radiotherapy protocols. Autologous Breast Reconstruction
oDespite a lack of robust evidence to support or oppose
immediate autologous reconstruction in patients known to
require Post Mastectomy Radiotherapy (PMRT) UK practice is
varied. Many centres routinely perform immediate autolo-
gous reconstruction with planned PMRT whereas others
follow the “Delayed-Immediate” [9] or “IDEAL” [10] method,
whereby patients known to require PMRT undergo imme-
diate implant/expander “spacer” reconstruction to maintain
the skin envelope with subsequent switch of implant/
expander to autologous tissue on completion of adjuvant
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cedures and cost but reduces concerns of long-term irre-
versible radiotherapy effects on flap reconstruction.
oPMRT following Immediate Autologous Reconstruction is
associated with fewer complications, fewer failures and
better quality of life in comparison to PMRT following im-
mediate implant based breast reconstruction [11].
oPMRT is detrimental to autologous reconstruction irre-
spective of whether performed in an immediate or delayed
fashion [12].
oImmediate autologous reconstruction with PMRT may
actually show lower [12] or at least similar complication
rates (including fat necrosis) [13] to that of delayed autolo-
gous breast reconstruction with a history of PMRT. However,
there is a higher incidence of revisional surgery in the im-
mediate group [12]. Overall satisfaction rates are similar for
all groups [13].
oDespite previous concerns that the volume of tissue may
interfere with planned delivery of chest wall radiotherapy,
Immediate autologous reconstruction with PMRT is onco-
logically safe [14].
oTherefore, these guidelines agree with recommendations
that immediate autologous reconstruction should still be
offered to all suitable patients expected to have PMRT [4].Technical factors
There should be a complete assessment of breast morphology
which may include the measurement and documentation of:
 Bra cup size/volume/ptosis of both breasts.
 Notch to nipple distance, nipple to inframammary distance.
 Base width/ height.
 Nipple sensation (particularly if considering mammoplasty).
 Breast/ chest wall asymmetry.
 Skin quality.
 Records from previous surgery.
 Record and assessment of damage from previous radiotherapy.
Assessment of technical factors should include:
 Breast cancer location and any skin involvement including
tumour proximity to nipple).
 Tumour to breast ratio (when considering mammoplasty/
perforator flaps).
 Suitability for nipple preservation in mastectomy and IBR.
 Assessment of donor sites and suitability (IBR and perforator
flaps).
 Options for contralateral surgery.Photographic assessment
 Medical photography must be available in all units. A full and
tiered consent process must be followed with each patient. Pre-
operative and successive post-operative views (including longer
term) should be taken for consenting patients undergoing OPBS.
A standard set of views should be acquired in a studio setting for
each patient.
 All digital images must be stored securely with limited access.
 Photographic images should be made available for the onco-
plastic breast MDM.
 Patient consent must be obtained to use Images for teaching and
or publication. The Institute of Medical Illustrators guidelines
should also be followed [15].2274Consideration of contralateral symmetrisation surgery
 Symmetrising surgery should be offerred to patients (immediate
or delayed) regardless of time of original surgery.
 If restrictions to contralateral surgery are apparent within the
host hospital area, the patients should be informed of local re-
strictions at the outset.
 Where possible consider immediate contralateral symmetrisa-
tion surgery, with specific attention paid to the likelihood of
adjuvant chemotherapy and whether surgical complications
could result in any delay with the delivery of chemotherapy (a
delay of over 8 weeks may lead to increased mortality) [16].
 In bilateral cases, a two-team approach is recommended to
shorten operating time which has been shown to reduce
complication rates [17].Considerations specific to delayed breast reconstruction
When DBR is considered, full clinical assessment should be
performed when indicated and the results should be available to
inform decision-making.
 A mammogram of the contralateral breast should have been
performed within the preceding 12 months.
 Consider re-staging in high risk patients prior to undertaking
major delayed total breast reconstruction surgery.
 Tamoxifen therapy is associated with a 2.3 fold increased risk of
venous thrombo-embolism(VTE) [18], this risk is exacerbated in
patients undergoing surgery after recent chemotherapy [19] or
those undergoing longer procedures [20]. Surgical procedures
lasting longer than 90min (total anaestheticþ surgical time) are
considered an indepenent risk factor for VTE [21]. Discontinuing
Tamoxifen for a period of 3 weeks results in 98% of the active
drug being eliminated from plasma [22]. A proposed manage-
ment algorithm based on current evidence stratifying risk of
VTE in patients on Tamoxifen suggests the following [22].oIn low risk patients (i.e. undergoing short procedures
(<90mins) with no/minimal other risk factors for VTE)⁃ Tamoxifen therapy can be continued pre and post operatively.
oIn moderate risk patients (i.e. undergoing longer proced-
ures (>90mins) or recent chemotherapy without other risk
factors for VTE)⁃ Tamoxifen should be discontinued for 3 weeks prior to surgery
but that it can be restarted immediately post-operatively at the
standard dose.oIn the high risk patients (those with other associated risk
factors for VTE, obesity, family history, comorbidities)⁃ Tamoxifen should be stopped for 3 weeks pre-operatively and
not restarted until 3 weeks post-operatively.
 At least 6 months should elapse before DBR following adjuvant
radiotherapy. Carrying out DBR >12 months after radiotherapy
may result in fewer post-operative complications [23].
There should be no time limit on DBR, however if such re-
strictions exist, the patient should be informed so plans can be
made to ensure a DBR is possible.Considerations specific to contralateral risk reducing mastectomy
(CRRM)
Contralateral risk reducing mastectomy when a breast cancer
has been diagnosed is a complex and emotive area for the patient
and the responsible team.
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definition of risk reduction, ie. reducing risk of death from a
contralateral breast cancer or the risk reduction of a new pri-
mary breast cancer in the contralateral breast.
 A patient is likely to substantially over-estimate risk of dying
from a contralateral breast cancer following diagnosis of the
ipsilateral cancer [24].
 There is very little evidence to support contralateral risk
reducingmastectomy as a tool to reduce the risk of breast cancer
death in all but the highest risk patients (ie. carriers of breast
cancer related pathogenic varient genes for example BRCA1).
 When considering such surgery in the immediate setting, the
patient is required to have the request discussed at anMDTwith
rapid psychology review.
 The oncologial factors need to be considered with the option of
delayed CRRM if there is a possibility of complications delaying
adjuvant treatments.
 When considering lifetime risk of a contraleteral breast cancer,
it is useful to consider the Manchester guidelines with a 25% or
over lifetime risk, used to sanction such surgery [25].
 Non surgical treatments (eg. endocrine therapy) for the index
cancer must be considered with the associated risk reduction in
contralateral breast tumour risk.
 If a patient is considering contralateral mastectomy with/
without reconstruction for symmetry purposes, discussion at an
oncoplastic MDT and psychological opinion prior to such sur-
gery should be sought [26].
 If the patient warrants a contralateral risk reducing mastectomy
but only wishes surgery on the symptomatic side and abdom-
inal flap reconstruction then they should be informed that
abdominal flap reconstruction can only be utilised once and
may be better served for a bilateral procedure if donor options
limited.
Patient information, decision making and psychosocial
support
Information provision
Patients differ in the amount and type of information they need
and the extent they wish to be involved in treatment decision
making. Compassionate, patient-centred care is essential and pa-
tient support and counselling may require more than one
consultation.
Discussions should take place in a private setting avoiding
emotive or persuasive language and the patient's understanding of
information received should be checked. Poor or inadequate pre-
operative information provision is associated with regret and
dissatisfaction with outcome [27]. Support and information should
also be available to partners and family members if required.
All patients should have easy access to:
 Information in languages other than English, and/or interpreters
if necessary
 Information that meets their changing needs over time in a
choice of formats (e.g. written information, multimedia
resources).
 Photos representing a range of procedures, outcomes, donor
sites with a variety of different patients at different time
intervals.
 Opportunities to discuss experiences with other patients (e.g.
through Breast Cancer Now's Someone Like Me service) [28].
 Details of local and national support/information services (see
Appendix).
 Contact details
2275oOut of hours care.
oPsychological and emotional support.All women should be informed about:
 All relevant oncological options for which they are suitable,
irrespective of whether they are available locally.
 If OPBS is contraindicated, this should be documented in the
patient's records.
 The full range of external prostheses available, with time scales
of when they can be utilised should be discussed.
 The number of procedures that may be needed to achieve an
acceptable outcome.
 Possible outcomes of OPBS including:
oThe look and feel of a reconstructed breast and the fact that
the exact aesthetic outcome cannot be predicted prior to
surgery.
oThe impact of surgery on the appearance of donor sites, if
appropriate
oThe time taken to adjust to a reconstructed breast and an
altered body image (typically 1 year or more), and the po-
tential impact on quality of life, emotional well-being and
intimacy.
oThe range of physical and psychological impacts of surgery
(e.g. discomfort, lack of sensation, self-consciousness, body
image issues) which contribute to (dis)satisfaction with
outcome. Planned additional procedures (e.g. nipple reconstruction, lip-
omodelling and contralateral surgery) which may be required
and the possibility of unplanned procedures.
 Their risks of complications associated with specific procedures.
 How to recognise and act on concerns about potential compli-
cations post-surgery.
 Whether implants will need to be routinely replaced in the
absence of concerns.
 Whether revision or replacement may be required for adverse
symptoms or to improve cosmetic outcomes in the longer term.
 The type of implant or expander to be used (if relevant), and
advised to retain this information.
 Possible longer-term outcomes, including:
oLocal and regional recurrence.
oAsymmetry.
oThe effects of weight changes and of contralateral ptosis.
oChronic seroma.
oChronic pain.
oShoulder stiffness and pectoral girdle disability.
oAbdominal hernias and other sequelae of abdominal flaps.
oFasciculation (muscle twitching) with muscle flaps.
oHypertrophic/ Keloid scarring.
oAxillary fullness following Latissimus Dorsi reconstruction.
oRevisional surgery including lipomodelling, flap, scar and
implant revisions.
oQuality of life, physical, cosmetic and psychological well-
being reported by patients undergoing different types of
reconstruction over time. Their hospital stay and the post-surgical period, including:
oThe likely length of stay.
oWhat they should take with them into hospital.
oLikelihood of post-surgical drains.
oWhen they are first likely to be able to look at their
reconstruction/ donor site(s) and what they can expect to see
at this time. They should be warned about any potential
swelling or shape abnormalities which may be present
initially and the likely duration this can take to settle [29].
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appointment where the histopathology results will be dis-
cussed, if appropriate, and a treatment plan will be agreed. Their post-operative recovery period regarding:
oExercise and physiotherapy.
oThe likely recovery time, time to return to normal activities,
work and driving, lifting, sport, exercise.
oPost-operative underwear/garments.
oContact details for difficulties arising out-of-hours or at
weekends. Ongoing research including, but not limited to, trials, national
audits, and registries
 Consent should follow established NHS and General Medical
Council (GMC) guidelines.
Early post-discharge phase:
 Discharge plans should be discussed as part of the consent
process with details of out-of-hours contacts, and arrangements
for nursing support and removal of drains, which should be
provided as locally as possible to the patient.
 A copy of the discharge letter should be sent to the GP and pa-
tient with their agreement.Supporting patients’ decision making
Decisions about OPBS are often complex and every effort must
be made to give all patients sufficient time and support to consider
their options with the operating surgeon(s) and reach a shared
decision [30]. A clinical nurse specialist should be available for
discussions about surgical options.
Shared decision making requires an understanding of what
matters to each patient, providing information that meets their
individual needs and is understood by them (see GMC guidelines
2020 [31]. Patients should be helped to consider what they want to
achieve from OPBS (i.e. their own goals), and their expectations
about outcomes should be clarified [32].
Decision aids/tools can be useful additions to the standard
provision of care and support for women considering OPBS [33,34].
Patients who are finding it particularly difficult to make a de-
cision should be identified and referred for additional support,
through clear referral routes.
Psychological assessment and support
 The OPBS service should have a documented strategy for psy-
chological assessment and support if needed.
 Patients should:
obe reassured that discussions about psychosocial aspects of
OPBS is a standard, routine part of care.
ohave easily available support if they experience complica-
tions, since these can be particularly distressing [35]. The psychological well-being of each patient and their potential
need for further support should be assessed at key points
including pre-operatively, during their hospital stay, prior to
discharge and during routine follow-up appointments by a
suitably trainedmember of theMDT (e.g. a Specialist Breast Care
Nurse (BCN) and/or Breast Reconstruction Nurse Specialist with
expert knowledge and skills in OPBS for Level 2 support).
 Where complex psychological difficulties are identified, referral
to specialised psychology services (Level 3 and 4) will be
required. Patients at high risk (previous psychiatric history, poor
coping skills, limited social support) should be monitored post-
operatively and further contact to establish psychological2276recovery should be negotiated and agreed with the patient. This
arrangement should be documented in the hospital notes.
 Established screening tools (e.g. HADS or PHQ9/GAD7) should




 Appropriate pre-operative markings should be undertaken in a
suitable private space that has an examination couch andmirror.
A chaperone should be present.Margins in breast conservation surgery
 ABS advises a 1 mm (1 mm) minimum clear radial margin is
achieved after breast conservation surgery for early invasive
breast cancer and for in situ cancer [36].
 Further surgery (re-excision or mastectomy) should be offered
where required to achieve clear margins.
 Routine excision of skin overlying tumour in breast conservation
surgery is not routinely recommended. Where tumours are
superficial however (close to or at the anterior margin) pre-
operative oncoplastic planning should consider the appropri-
ateness of oncoplastic excision of the overlying skin to facilitate
achieving a clear anterior margin.Mastectomy
Oncological outcomes following SSM & NSM
A number of observational studies have reported on the short to
medium term oncological outcomes of SSM and NSM in women
undergoing therapeutic or risk reducing mastectomies [37e42].
They report low rates of subsequent breast cancer development.
However a Cochrane review of NSM reported the evidence to be of
low quality and was inconclusive due to high risk of selection bias
[43]. Given the unlikely reporting of any randomised data long term
follow up studies in this cohort are essential to ensure low rates of
loco-regional breast cancer incidence are maintained.
NSM and SSM are contraindicated in patients with inflamma-
tory breast cancer and caution should be applied in considering
these techniques in more locally advanced cancers (e.g. T4 tu-
mours) [44].
Skin sparing mastectomy (SSM)
The aim of SSM in patients is removal of all breast glandular
tissue, whilst preserving the native skin envelope which involves
preserving a viable blood supply to the entirety of the envelope of
the breast.
Therefore, precise surgical technique is required to dissect
exactly within the plane between subcutaneous fatty tissue car-
rying blood supply to the skin envelope and the underlying para-
nchyma (“the mastectomy plane”) [45e47]. Such technique allows
for maximal removal of breast glandular tissue and minimal inci-
dence of mastectomy flap necrosis.
Thicker mastectomy flaps are more likely to prevent damage to
subcutaneous vessels but risk of leaving breast tissue in situ.
Studies examining the presence of residual breast tissue following
SSM have shown a greater prevalence of breast terminal ductal
lobular units in the presence of thicker mastectomy skin flaps
[46,48]. Certain areas of themastectomy planemay harbour greater
risk of residual breast epithelium, in particular the lower outer
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The incidence of mastectomy skin flap necrosis is increased in
the presence of smoking, previous radiotherapy, diabetes, obesity
and multiple comorbidities [50,51].
Choice of incision can also affect incidence of mastectomy flap
necrosis but there is no evidence that use of differing electrocautery
devices or scalpel dissection affect necrosis rates [52,53].
SSM is considered oncologically safe in the following clinical
settings; risk reduction surgery in high risk patients, early stage,
biologically favorable, invasive breast cancer or Ductal Carcinoma
In-Situ (DCIS) [54].
Recommendations:
The optimal thickness of a SSM flap should be judged for each
individual patient.
Special consideration should be given to maintaining dissection
in the plane between subcutaneous adipose tissue and underlying
breast parenchyma, particularly in the lower outer quadrant of the
breast. If there is concern intra-operatively about potential prox-
imity of malignant tissue at the anterior mastectomy margin, the
relevant area on the mastectomy skin flap should be marked with a
radiologically visible subcutaneous clip or a percutaneous non-
absorbable suture. This will facilitate reoperative surgery to
remove involved dermis should this be noted at the postopertive
MDT.
Wise pattern incisions (“inverted T incisions”) may increase
rates of skin flap necrosis in some circumstances.
Nipple sparing mastectomy (NSM)
The technique for NSM is similar to SSM in the development of
uniform thickness mastectomy flaps with precise adherence to
surgery within the mastectomy plane. However, in NSM, the
nipple-areolar complex is left in situ. The presence of the natural
nipple-areolar complex is associated with psychological and
aesthetic benefits for women [55,56]. The process of nipple pres-
ervation requires a balance between two competing factors;
removing the maximum amount of retro-areolar breast tissue
whilst maintaining a viable blood supply to the nipple.
Whilst the ducts of the breast should be excised during surgery,
there is no clear evidence on how aggressively ducts should be
excised from the nipple and retroareolar area.
Capturing occult malignancy can be done by sending retro-
areolar/ nipple core tissue for histological examination separately
to the main mastectomy specimen [42,57,58].
Leaving a 3 mm rim of tissue at the nipple areolar complex
preserves at least 66% of the nipple microvessels [59]. Rates of
nipple necrosis are increased with transareolar or circumareolar
incisions, in smokers and patients undergoing previous breast
irradiation [47,60].
NSM is considered oncologically safe in the following clinical
settings; risk reduction surgery in high risk patients, early stage,
biologically favorable, invasive breast cancer or DCIS at least 2 cm
from the nipple, imaging findings indicating no nipple involve-
ment, no nipple discharge and no Paget's disease [44].
Recommendations:
Tissue excised from the nipple areolar complex should be sent
for histological examination separately from the main mastectomy
specimen. In NSM performed for risk reduction purposes, there is
no evidence that intraoperative frozen section analysis of retro-
areolar tissue is of benefit.
The mastectomy specimen itself should have the site of the
recently detached nipple areolar complex clearly marked in order
for accurate localisation of any occult malignancy should this be
discovered. If there is concern about potential proximity of malig-
nant tissue at the anterior mastectomy margin (abutting the skin),
the relevant area on the mastectomy skin flap should be marked2277with a radiologically visible subcutaneous clip or a percutaneous
non-absorbable suture. This will facilitate reoperative surgery to
remove involved dermis should this be noted at the postopertive
MDT.
Transareolar and circumareolar incisions are associated with
higher rates of nipple areolar complex necrosis in comparison to
radial and inframammary fold incisions [61e64].
NSM should be used with caution inwomenwho smoke or have
had previous breast/ chest wall irradiation [65].
Breast conservation with oncoplastic techniques
Where it is oncologically safe, breast conservation should be
considered in all patients. Techniques have evolved to increase the
availability of breast conservation.
Equipment required for oncoplastic breast surgery within the
operating theatre includes:
 Mammographic quality monitor(s). The resolution should be
sufficient to enable satisfactory visualisation of fine micro-
calcifications (eg 5 megapixel) [66]. Suchmonitors are usually of
a higher resolution than standard monitors used for viewing CT
images.
 Equipment or facilities to enable immediate intraoperative
specimen radiography [67].
 Equipment for sentinel lymph node localisation.
 Equipment, according to local protocols, for localisation and
surgery of impalpable and screen detected lesions.
All equipment should be regularly serviced and there should be
contingency planning in the event of failure of a piece of equipment
(eg back-up equipment).
When performing volume displacement or replacement pro-
cedures the tumour bed should be localised with titanium clips to
aid accurate delivery of radiotherapy according to local protocol.
Volume displacement techniques
 In the larger, more ptotic breast, breast reduction techniques in
the form of therapeutic mammoplasties facilitate removal of
large areas of tissue, with concomitant reshaping of the breast.
Therapeutic mastopexies can also produce a similar result in
smaller breasts.
 Care should be taken to reduce potential wound healing com-
plications/fat necrosis which could potentially delay adjuvant
treatment(s). Examples include considering longer vertical limb
lengths, narrower wise patterns, wider pedicle bases and lower
tension closure in comparison to aesthetic breast reduction/
uplift surgery.
 Technically in nipple preserving therapeutic mammoplasty/
mastopexy it is often easier to base the nipple on a separate
pedicle from that used to fill the defect (secondary pedicle) as it
allows greater freedom of inset with less risk of nipple
compromise.
Where the nipple has to move a long distance or looks
compromised on table one option to consider is converting the
nipple-areolar complex to a free nipple graft.Volume replacement techniques
 Volume replacement techniques enable breast conservation for
larger tumours in smaller breasts. For lateral defects, the lateral
intercostal artery perforator (LICAP) and lateral thoracic artery
perforator (LTAP) flaps can be used. Caudal defects can be filled
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Whereas medial, and even upper inner quadrant defects, can be
filled using themedial intercostal artery perforator (MiCAP) flap.
 Do not compromise potential total breast reconstruction donor
sites in high risk patients with few donor site options. I.e.
extended LICAP flaps may compromise the ability to perform (or
volume available) in an extended LD flap.Partial breast reconstruction
 In patients with larger defects (I.e. one-quarter to one-half of the
breast) other options could be considered such as the Thor-
acodorsal Artery Perforator (TDAP) flap or free mini-transverse
upper Gracilis (TUG) flap.
Where larger excisions are performed and more complex
reconstructive techniques are used, clear margins should be
ensured, prior to reconstruction (i.e. fill cavity with water and
await formal pathology prior to reconstruction as second stage
within a few weeks or fresh frozen section).
Total breast reconstruction
When a mastectomy is oncologically dictated, there are various
methods used to perform total breast reconstruction. These can
either be entirely implant based, autologous or a mixture of both
techniques.
Implant based breast reconstruction
Implant based reconstruction can be used, with either a fixed
volume implant or tissue expander being placed in the subpectoral
or prepectoral position, with support from an acellular dermal
matrix or dermal flap. These techniques can be used as a permanent
solution to breast reconstruction, or as a delayed-immediate solu-
tion, with a view to preserving the skin envelope and performing a
delayed autologous reconstruction.
Patients should be informed:
 Modern breast implants do not have a specific lifespan and do
not need to be routinely replaced in the absence of concerns.
 Revision or replacement may be required for adverse symptoms
or cosmetic deformity in the longer term. Patients should ask
their GP to refer them back to their original provider for
assessment.
 That there are differences between tissue expanders and fixed
volume implants, between saline and silicone-based devices
and between textured and smooth coatings.
 Of the type of implant or expander used, which they should be
advised to retain.
 Up to 1 in 10 patients experience loss of their implant in the first
3 months after surgery [68].
 Up to 1 in 4 patients may require revisional surgery in the first
10 years [69].
Patients should also receive information about other potential








 Implant malposition.2278 Breast Implant Associated e Anaplastic Large Cell Lymphoma
(BIA-ALCL).Acellular dermal/ synthetic matrices (ADM's). The use of implant
based reconstruction accounts for 53% of immediate re-
constructions following mastectomy in the UK [70]. The majority of
these are now being performed with a biological or synthetic mesh
[68]. The advantages of biologic or synthetic mesh used as an
adjunct for implant based breast reconstruction over traditional
total submuscular techniques are to improve lower pole projection,
the potential to go straight to permanent breast implant, reduced
postoperative pain, improved aesthetic outcome, and decreased
operative time [71]. Despite widespread adoption in the UK, these
procedures are associated with morbidity [68].
There is no clear consensus on the ideal biologic or synthetic
mesh.
Specific points for discussion are.
 The origin of the specific mesh should be discussed.
 Whether the mesh remains permanently or is expected to be
absorbed.
 Patients should be informed of local and global experience with
the mesh used including uncertainty regarding long term
outcome.
 Knowledge and acceptance that the reconstruction involves a
breast implant.
 Patients should be aware that revisional surgery is frequent in
the early stages following reconstruction.
 That a drain may be left in-situ for up to two weeks.
Patients need to be aware of the risks of complications, local and
personal complication rates. Complications are common in implant
only mesh assisted or dermal sling procedures. By 3 months na-
tional rates are [68].
 Readmission - 18%.
 Infection - 25%.
 Reoperation - 18%.
 Implant loss - 9%.
Patients opting for a single-stage procedure must be informed
preoperatively of the possibility of a two-stage procedure using an
expander because of possible impaired vascularisation of the skin
flaps.
Patients should be aware that long term results of implant-
based reconstruction may deteriorate and subsequent planned
surgery for cosmetic concerns may be required. Funding for further
procedures may become limited. Cosmetic outcome of further
procedures may be limited.
Surgeons should be familiar with and adhere to the ABS &
BAPRAS Guidelines on ADM based breast reconstruction [1,2].
Strategies to decrease implant related complications. Implant based
reconstruction techniques inevitably carry some risk, most notably
implant failure and explantationwhich is costly to both the patient
and providers [71]. The National Mastectomy and Breast Recon-
struction Audit demonstrated an implant loss rate of 9% at 3
months in IBR and 7% in delayed reconstruction [72]. However, the
current national target is to have less than 5% implant loss rate at 3
months post-operation.
Factors shown to increase implant failure include:
 Smokers (consider using nicotine replacement therapy).
 Patient BMI>30.
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 Concomitant axillary clearance.
 Using implants >500 cc.
 Neo-adjuvant chemotherapy.
 Pre-operative radiotherapy.
Pre-, intra- and post-operative protocols [17,73] have been
developed and shown to reduce implant loss rates at 3 months [73].
Pre-operative risk reducing measures include:
 Careful patient selection to minimise patient risk factors.
 Single dose of prophylactic intravenous antibiotic at induction.
Intra-operative risk reducing measures include:
 Reduce personnel in theatre and avoid opening doors (use of
locks and signs).
 Reduce operative time- use 2 surgical teams for bilateral cases.
 Consider using laminar air flow if available.
 All theatre personnel to wear facemasks when implant is
opened.
 Patient to be warmed for the duration of surgery.
 Nipple shields to be applied for unilateral cases.
 Patient to be prepped with alcoholic chlorhexidine.
 Surgeons and scrub staff to double glove, surgeons and scrub
staff to change outer gloves to a clean pair prior to handling the
implant.
 Clean drape to be placed before implant insertion.
 Implant only handled by the surgeon (following glove change).
 Trim skin edges.
 Use bacteriostatic sutures and skin glue to seal the wound.
 Tunnel drains.
 Consider using tissue expanders and negative pressure dress-
ings in high risk patients.
Post-operative risk reducing measures include:
 Consider selective use of extended antibiotic prophylaxis in
those patients deemed “high risk” for infection.
 Drains to be removed when draining <30 mls on 2 consecutive
day.
 Early debridement for small wound problems and early outpa-
tient review.Radiotherapy
 Patients requiring post-operative chest wall radiotherapy have
an increase in complications.
 There is an increased risk of capsular contracture post radio-
therapy. ADM does not increase the risk of capsular contracture
post radiotherapy and there is emerging data to suggest it may
potentially reduce the severity of capsular contracture [74]
however, there is no definitive data.
 Those who have received radiotherapy prior to reconstruction
have an increased risk of major complications and implant loss
[75].Information about implants. The Medicines and Healthcare prod-
ucts Regulatory Agency (MHRA) has reviewed literature on the
safety of breast implants and has concluded that implants do not2279increase the risk of connective tissue disorders [76] or the risk of
breast cancer [77].
Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-
ALCL)
 In 2016 the World Health Organisation (WHO) described BIA-
ALCL as a provisional entity with specific diagnostic criteria
[78]. The UK incidence is regularly updated by the MHRA and
FDA. Cases of BIA-ALCL have occurred between 2 and 28 years
after breast implant insertion with the average time being 8
years. It is most likely to present as a seroma.
 Most of the cases worldwide have occurred with textured breast
implants as opposed to smooth. There are however benefits of
textured implants in reconstruction which can be considered.






 Breast Implant Illness (BII) is a term used by patients who have
breast implants and experience a variety of symptoms that they
feel are directly connected to their silicone breast implants.
Breast Implant Illness is not a medical diagnosis and there is no
proven association with breast implants. The symptoms include
tiredness, “brain fog”, joint aches, immune-related symptoms,
sleep disturbance, depression, hormonal issues, headaches, hair
loss, chills, rash, hormonal issues and neurological issues.
 There is currently no scientific evidence to confirm this pro-
posed link or any diagnostic test to show that a patient suffers
from such a condition. Research continues in this area to
establish if all of the symptoms that patients describe can be
brought together into a single diagnosis. Some patients do
report that their symptoms improve if their implants are
removed but this is not true for all.





ABS, BAAPS and BAPRAS advise that if individuals with breast
implants experience breast swelling, lumps or change in shape they
should seek medical advice. They also state: “If you think your
breast implants are causing general health problems you should
seek the advice of your original implanting surgeon or the hospital/
clinic where the implant operation took place. If you cannot contact
either of those, please consult your GP.” [79].
 All patients having BRwith Implants must have this discussed as
part of informed consent.Breast and Cosmetic Implant Registry. The Breast and Cosmetic
Implant Registry (BCIR) was opened on 10 October 2016. It captures
the details of all breast implant procedures completed in England
and Scotland by both the NHS and private providers [80].
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to carry out this work in response to recommendation 21 of the
Keogh Review of the Regulation of Cosmetic Interventions [81].
The registry records the details of any individual who has breast
implant surgery, for any reason, so they can be traced in the event of
a product recall or other safety concern relating to a specific type of
implant. It also allows the identification of possible trends and
complications relating to specific implants.
All providers of breast implant surgery are expected to partici-
pate. This is mandatory in the NHS.
Total autologous breast reconstruction
Total autologous reconstruction includes pedicled and free flaps.
The most commonly used pedicled flap is the extended latissimus
dorsi flap. Whilst the deep inferior epigastric artery perforator
(DIEP) flap accounts for the most commonly used free flap. Other
autologous options for women who are not suitable for DIEP flaps
include the muscle sparing transverse rectus abdominis myocuta-
neous (MS-TRAM), transverse upper gracilis (TUG), profunda artery
perforator (PAP), lumbar artery perforator (LAP), superior gluteal
artery perforator (SGAP) and inferior gluteal artery perforator
(IGAP) flaps.
Many surgeons now consider the DIEP flap as the gold standard
in free autologous total breast reconstruction with the literature
supporting low (2.2% total/ 3.1% partial) flap failure rates in uni-
lateral flaps [82] and re-operation for any complication as 15.9%
[83].
In addition, autologous techniques can be augmented with
lipofilling, or implants can be used to augment the volume of
autologous reconstructions, such as Latissimus Dorsi flaps.
UK National Flap Registry. The UK National Flap Registry (UKNFR) is
a registry for all pedicled and free flaps including breast.
The registry has been live since August 2015 and offers the
‘Surgeon Dashboard’ (launched in July 2017) allowing users to
download personal data (numbers, case mix, gender, age, success
rate, return to theatre).
Lipomodelling
Delayed lipomodelling has been shown to be oncologically safe
for the correction of breast conservation defects; though good re-
sults can be difficult to achieve following radiotherapy. A delay of 6
months after radiotherapy or until the first annual surveillance
mammogram is suggested [84]. Enrichment of the fat grafts using
adipose-derived regenerative cell (ADRCs) has also been shown to
be safe and efficacious for this purpose [85].
Immediate lipomodelling at the time of breast conservationmay
reduce the incidence of postoperative deformity but should be
considered experimental until long term results are published
[86,87].
Lipomodelling can improve volume and contour in implant or
autologous total breast reconstruction [88,89]. Lipomodelling has
been shown to improve the quality of irradiated tissues, especially
in implant based procedures [90].
Care should be taken in the selection of donor sites for fat har-
vest in patients who may require subsequent total autologous
reconstruction (i.e. don't use the lower abdomen as a donor site for
fat harvest to improve implant coverage in a patient highly likely to
require switch to autologous tissue such as a DIEP flap in future).
The use of lipomodelling as the sole technique for breast recon-
struction has been limited to selected patients because of the
number of procedures required to achieve a satisfactory volume [91].
It is best suited to small-breastedwomenwith suitable donor sites in
whom other types of reconstruction may not be possible or desired.2280Radiological surveillance after OPBS and total breast reconstruction
Bilateral annual surveillance mammography is recommended
after OPBS. During the first 6e12 months after surgery and radio-
therapy post treatment changes are most likely to occur and can be
difficult to accurately assess radiologically [92]. A 12 month delay
following OPBS is recommended. Radiology should be informed of
any patient who undergoes lipomodelling as a secondary
procedure.
There is no indication for ipsilateral imaging following mastec-
tomy and either implant or autologous reconstruction, recurrence
occurring in the mastectomy flaps. Patients should undergo
contralateral annual mammographic surveillance.
Routine breast MRI scanning is not recommended unless
women carry additional risk factors [93].
Surgical ERAS considerations
As partial and total breast reconstruction techniques have
improved, surgical teams have aspired to reduce perioperative ef-
fects, such as starving, increased catabolism, nausea, vomiting and
dependence on opiates whilst reducing length of stays and
reducing complication rates by implementing enhanced recovery
after surgery (ERAS). These evidence based changes can be made to
patient pathways to improve patient care [94,95]. Teams should
aspire to perform much of their implant based breast reconstruc-
tion as day case procedures and aim to safely discharge DIEP pa-
tients on day 3.
 Optimisation of patients: stop smoking/using nicotine contain-
ing products for a minimum of a month, reduce body mass in-
dex, optimise diabetic control [96].
 Preoperative imaging for perforator flaps has been shown to
reduce flap harvest time, operation time and significantly
reduce complications in DIEP flap breast reconstruction [97].
 Fasting: Patients should stop solid food intake and be encour-
aged to drink clear fluids according to local protocols prior to the
procedure to minimise pre-operative dehydration.
 Carbohydrate loading; for longer procedures usingmaltodextrin
based drinks may be considered to reduce the catabolic effects
of surgery [98].
 Venous thromboembolism (VTE) prophylaxis: VTE complica-
tions in patients undergoing DBR (0.41%) and mastectomy with
immediate reconstruction (0.52%) are higher than those un-
dergoing wide local excision (0.13%) and mastectomy (0.29%)
alone [99]. Unless contraindicated, patients should receive low
molecular weight heparin with intermittent pneumatic
compression until mobile.
 Surgical Site Infection can be reduced by:
o Chlorhexidine based skin preparations [100,101].oProphylactic antibiotics [102,103].
oAntibiotic washout of the breast cavity [104]. The length of use of preventative antibiotics is harder to quan-
tify. Many units ask patients with implant based reconstruction
to continue oral antibiotics until the drains are out, however no
randomised controlled trial has been carried out to assess this
[17].
 Perioperative nausea and vomiting: 5-hydroxytyptamine-3 an-
tagonists (e.g.ondansetron) reduce post-operative nausea and
vomiting, whilst dexamethasone reduces nausea, vomiting and
pain.
 Multimodal analgesia: Paracetamol and non-steroidal anti-in-
flammatory drugs can be given pre-,intra- and post-operatively
[95]. Pregabalin reduces post-operative analgesia requirements
and pain in mastectomy patients [105]. Analgesia should aim to
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recommended as the first-choice regional analgesic technique,
whilst pectoral nerves block may be used as an alternative to
paravertebral block [95]. Local anaesthetic wound infiltration
may be added to regional analgesia techniques. Transversus
abdominal plane (TAP) blocks have been used successfully in
DIEP patients [106].
 Reducing Bleeding/Haematoma: Tranexamic acid, an anti-
fibrinolytic agent, reduces mortality in bleeding trauma pa-
tients when administered early [107]. There is increasing evi-
dence that tranexamic acid reduces bleeding in the elective
surgical setting (particularly orthopaedic surgery) and subse-
quent need for post-operative transfusion. [108,109] It is now
increasingly used in both elective oncological and aesthetic
surgery due to the potential benefits of decreased drain output,
decreased swelling, decreased bruising [110] and decreased
haematoma rate [111].
 Reducing Seroma: The placement of “quilting” or “progressive
tension sutures” evenly distributes tension over the whole
wound rather than at the incision site, decreases shearing forces
and reduces dead space. It reduces drain volumes and incidence
of post-operative seroma formation in extended LD [112] and
DIEP donor sites [113]. In established seromas the use of intra-
cavity Triamcinolone instilled after aspiration reduces re-
accumulation [114].
 Prevention of hypothermia: Methods should be employed to
warm operating rooms, tables and the patient to prevent
hypothermia.
 Peri-operative fluids: Fluid balance should be carefully moni-
tored. Fluid overload can be as detrimental as underload. The
use of Vasopressers tomaintain adequatemean arterial pressure
in already well hydrated patients, are not associated with major
flap complications such as thrombotic events and total flap loss.
Although they may be associated with an increase in minor
complications such as delayed healing, fat necrosis, seroma and
infection [115].
 Early feeding: encourage fluids and return to a normal diet
within 24 h. Prescribing laxatives can help counteract any effects
of opiates, if used.
 Incisional Negative Pressure Wound Therapy (iNWPT): There is
randomised control evidence looking at the use of iNWPT in
breast reduction surgery but not in oncoplastic breast surgery. In
breast reduction surgery iNPWT is associated with a significant
reduction inwound breakdown and improved scar quality [116].
In oncoplastic breast surgery iNPWT reduces seroma, rates of
skin necrosis, time for wound healing and surgical site infection
[117e119]. There are also reports of reduction in implant loss
rates in prepectoral breast reconstruction when iNPWT is uti-
lised and resultant cost-savings in comparison to management
of total reconstructive failures to justify their use [120,121].
There is NICE guidance advocating the use of iNPWT in high risk
patients and wounds [122].
 Mobilise early and remove urinary catheters in the early post-
operative course.
 Each unit should have post-operative flap monitoring protocols
and policy for takeback.
 Post discharge: Early physiotherapy, supervised exercise and
early follow up phone call from breast care nurse. Consider bra/
support garments 24/7 for 6/52
 A nominated theatre teamwith expertise in the preparation and
use of equipment and materials required for microvascular
surgery and other major reconstructive procedures including
primary, revision and salvage surgery.
 A nursing team which should include a BCN or Breast Recon-
struction Nurse Specialist appropriately trained in supportive2281care with specialist knowledge of OP techniques. In addition, a
specialist nurse with plastics training will also be involved in
managing complex dressings and nipple tattooing.
 A nominated ward team with expertise in monitoring, manage-
ment and mobilisation of patients following microvascular
surgery.Training in oncoplastic breast surgery in the UK
Oncoplastic breast surgery is incorporated in both the General
Surgery Curriculum and the Plastic Surgery Curriculum.
 Surgeons in training via the General Surgery pathwaywishing to
pursue a career in Oncoplastic Breast Surgery currently must
declare a subspecialist interest in Breast Surgery. Their final
years of training are dedicated to Breast Surgery and they are
expected to obtain experience in Oncoplastic Breast Surgery
prior to the award of Certificate of Completion of Training (CCT).
 Surgeons in training via the Plastic Surgery pathway wishing to
pursue a career in Oncoplastic Breast Surgery would normally
dedicate their final years of training to gaining additional
experience in Breast Reconstruction within their programme
with many undertaking an additional fellowship in Breast
Microsurgery. Additional training in breast Oncology may also
be undertaken by some trainees.
Advanced training in Oncoplastic Breast Surgery has been
available in the UK via competitive application to the Oncoplastic
Breast Surgery Training Interface Group (TIG) Fellowship since
2002. These National Fellowships; overseen by both ABS and
BAPRAS via the Oncoplastic Breast surgery TIG committee; are open
to applicants from General Surgery trainees with a subspecialist
interest in Breast Surgery and Plastic Surgery Trainees. The nine 12-
month fellowships are designed to give the senior trainee immer-
sive inter-speciality exposure and experience in Oncoplastic Breast
Surgery in one of the approved specialist oncoplastic breast surgery
training units throughout the UK. During this time trainees are
supernumerary. As well as focusing on gaining the background
knowledge and operative skills required by an Oncoplastic Breast
Surgeon, trainees are encouraged and supported in obtaining skills
requisite for independent Consultant practice through compulsory
courses and events. The fellowships were traditionally undertaken
Pre-CCT award but as from 2021 applications will only be open to
Post-CCT trainees.
Data collection and audit requirements
On-going, prospective audit is essential for the provision and
maintenance of a high-quality OP surgical service and as a mini-
mum, individual patient care should be audited against agreed
performance indicators and target standards including clinical,
cosmetic, and patient-reported outcomes.
Each unit should identify an oncoplastic audit lead and have a
data manager who assumes overall responsibility for this process.
There should be a secure system in place to accurately record
complications (early and late)
All patients should be asked to report outcomes, at agreed time
intervals, using validatedmeasures e.g. the ‘Breast Q’ questionnaire.
Summary audit data relating to key performance indicators
should be presented at department audit meetings. These results
should be available for scrutiny by NHS performance monitoring
organisations eg the Care Quality Commission (CQC), Safety and
Quality Assessment for Sustainability (SQAS), Getting it Right First
Time (GiRFT) and other similar bodies.
(continued )
No. Quality criteria
Eligible patients are invited to take part in local and national clinical trials of
OPBS/BR
Target: Screening for eligibility for clinical trials and national audits occurs
in 100% of OPBS/BR patients
17 Implant Breast Reconstruction patient details should be entered into the
Breast Implant Registry*
Target: 100% of Implant Based Breast Reconstruction patient details are
entered into the Breast Implant Registry
*(where access to registry exists)
18 Flap-based Breast Reconstruction patient details should be entered into the
UK National Flap Registry*
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Patients must be supported through decision making, surgery
and recovery if they are to have good outcomes that meet their
needs and expectations. Since the first UK oncoplastic guidelines
were published in 2007 [123], OPBS has become standard for the
surgical management of breast cancer providing good oncological
outcomes and acceptable aesthetic results. Oncoplastic surgery is
complex and not indicated for every patient. Careful patient se-
lection and the most appropriate surgical technique must be
considered to minimise complications and ensure low rates of local
recurrence.Target: 100% of Flap Based Breast Reconstruction patient details are entered
into the UK National Flap Registry
*(where access to registry exists)
19 ERAS should be adopted by all units to reduce length of stay
Target: All units should adopt ERAS methodologyComplete list of quality criteria
The complete list of quality criteria set out in this guideline are
provided below:No. Quality criteria
1 Breast Reconstruction is discussed with all suitable patients requiring a
mastectomy
Target: Breast Reconstruction is discussed in >90% of all suitable patients
requiring a mastectomy
2 When a referral for OPBS is made from one MDT to another MDT, full
clinical, radiological and histopathological information is made available at
the time of the referral and reciprocated with a clear plan for ongoing care
responsibility
Target: Full information is available in 100% of patients referred and
following treatment
3 The oncological and reconstructive management is discussed at the MDM.
Target: The oncological and reconstructive strategy is discussed at the MDM
in 100% of patients suitable for OPBS
4 Medical photography (pre- and post-operative) is part of the clinical record
Target: Medical photography is offered in 100% of BR patients
5 Patients have access to a BCN or equivalent key worker with expertise in
OPBS Target: Access to a key worker with expertise in OPBS and
psychological assessment is available in 100% of patients
6 Patients receive information in a format and level of detail that meets their
individual needs.
Target: Information about the risks and benefits of breast reconstruction/
oncoplastic procedures are provided to 100% of patients undergoing OPBS
7 Clinical Specialist and psychological reviews take place at key points
Target: Review by the Clinical Specialist occurs in 100% of cases
8 Physiotherapy services should be available for patients undergoing OPBS
8: 100% availability of Physiotherapy services
9 Implant loss at 3 months following BR is assessed and audited (over 12
month period)
Target: Complications leading to implant loss occur in <5% of cases at 3
months
10 Flap loss following BR is assessed and audited (over 3 year period)
Target: Total free flap loss occurs in <5% of cases
Pedicled Flap Loss occurs in <1%
11 Unplanned return to theatre following BR/OPBS is assessed and audited
Target: Unplanned return to theatre occurs in <5% of cases for non-free flap
IBR, and <10% of cases for free-flap IBR
12 Unplanned re-admission is assessed and audited for BR/OPBS
Target: Unplanned readmission occurs in less than 10% of cases within 3
months
13 Post-operative complications, return to theatre and length of stay are
audited
Target: There is a regular audit and discussion of all patients with post-
operative complications
14 Patients' are invited to report their satisfaction with BR/OPBS using
validated outcome measures
Target: At 18 months, > 90% of BR/OPBS patients are invited to report their
satisfaction with BR/OPBS using validated outcome measures
15 Margins should be clear following OPBS/BR and this should be assessed and
audited (over a 12-month period)
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APPENDIX. SUPPORT SERVICES AND PATIENT INFORMATION
 BAPRAS guide to breast reconstruction: http://www.bapras.org.
uk/docs/default-source/Patient-Information-Booklets/web_
2018-bapras-abs-breast-recon-guide.pdf?sfvrsn¼2
 Breast Cancer Now: https://breastcancernow.org/










 Maggie's Cancer Caring Centres: www.maggiescentres.org
 Breast reconstruction: your choice. Rainsbury R. Straker V. (Eds)
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